|
Areas of Practice For more than 20 years, Joel has advised companies in the healthcare, medical device, pharmaceutical and biotech industries. His clients include pharmaceutical, medical device and biotech manufacturers; managed care and pharmacy-benefit management companies; physician practices; physician-practice management firms; companies developing clinics in retail settings; and companies engaged in the development and management of ancillary-services facilities. Joel assists clients in evaluating strategic relationships and transactions as they relate to clients’ business goals and objectives, and then structures and negotiates transactions suited to the companies’ objectives. He also advises companies on compliance, pricing, advertising and promotion considerations relative to healthcare laws and regulations, including federal fraud-and-abuse and Stark laws and regulations. A client interviewed by Chambers & Partners for the 2007 edition of America’s Leading Lawyers for Business praises Joel’s good mix of legal and business sense he takes your business objectives and formats them into a legal framework. Representative Experience Negotiated the in-licensing for the domestic development, regulatory approval and commercialization of a drug developed abroad. For a healthcare company, negotiated the acquisition of a business to serve as the platform for a product line in a new business sector. Negotiated the NIH license for a biologic product developed under a cooperative research and development arrangement with the NIH. Negotiated an arrangement with a vaccine manufacturer in central Europe for the joint development and contract manufacture and supply of vaccine developed in the U.S. Prepared contract documentation for a drug innovator to use for its clinical studies required to support regulatory approval. Negotiated and documented a pharmaceutical company’s engagement of a contract research organization (CRO). Joel lectures frequently on industry topics related to strategic transactions including mergers and acquisitions, licensing, and strategic business planning. He is also a contributing author of A Guide to Biotechnology Finance (2005).
| 